{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:28:30Z","timestamp":1791912510398,"version":"4.3.4"},"reference-count":46,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2017,8,29]]},"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction, characterized by fatigable weakness of the extraocular, bulbar, and limb musculature; prevalence is estimated at 14 to 32 per 100,000 in North America. Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, resulting from clonal expansion of B-cells in blood, marrow, and secondary lymphoid tissues. The simultaneous presentation of MG and CLL is exceedingly rare. This article presents the case of 71-year-old man diagnosed simultaneously with MG and CLL. His MG was severe and refractory to treatment; therefore, a strategy of treating his coexisting CLL with obinutuzumab and chlorambucil was pursued. Following 6 cycles of obinutuzumab and chlorambucil, his CLL is in remission and his MG is almost entirely undetectable. This is the first case report describing the use of obinutuzumab, a novel anti-CD20 monoclonal antibody, in a patient with concurrent MG and CLL.<\/jats:p>","DOI":"10.3233\/jnd-170211","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T11:43:35Z","timestamp":1504007015000},"page":"251-257","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia"],"prefix":"10.1177","volume":"4","author":[{"given":"Angela","family":"Russell","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Yaraskavitch","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fok","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Chhibber","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Street","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Korngut","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-829585"},{"key":"ref002","unstructured":"Myasthenia Gravis Foundation of America, Inc. [homepage on the Internet]. Clinical overview of myasthenia gravis; 2015 [reviewed 2015 June; cited 2017 Jan 10]. Available at myasthenia.org\/HealthProfessionals\/ClinicalOverviewofMG.aspx"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2015.10.009"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020712-163955"},{"key":"ref006","unstructured":"American Cancer Society [homepage on the Internet]. What are the key statistics for chronic lymphocytic leukemia? 2016 [reviewed 2015 June; cited 2017 Jan 10]. Available at www.cancer.org\/cancer\/leukemia-chroniclymphocyticcll\/detailedguide\/leukemia-chronic-lymphocytic-key-statistics"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1967.00300050073012"},{"key":"ref008","first-page":"114","volume":"5","author":"Talvalkar GV","year":"1968","journal-title":"Indian J Cancer"},{"key":"ref009","first-page":"2252","volume":"77","author":"Vogel JM","year":"1977","journal-title":"New York State Journal of Medicine"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1989.tb00257.x"},{"key":"ref011","first-page":"379","volume":"19","author":"Kaplanski G","year":"1990","journal-title":"La Presse Medicale"},{"key":"ref012","first-page":"140","volume":"142","author":"Minard P","year":"1991","journal-title":"Ann Med Interne"},{"key":"ref013","unstructured":"ReyJ, AttarianS, DisdierP, et al. Myasthenia gravis and chronic lymphocytic leukemia: A lucky association? Le Revue de Medecine Interne2001;22:1129\u201330."},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500063054"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.02.005"},{"key":"ref016","first-page":"43","volume":"68","author":"Bawa AS","year":"2002","journal-title":"Hospital Physician"},{"key":"ref017","first-page":"5","volume":"474512","author":"Romi F","year":"2011","journal-title":"Autoimmune Diseases"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.615426"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2005.05.009"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1971.79"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11011.x"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199907000-00037"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1007\/BF00878532"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.5.1076"},{"key":"ref025","first-page":"10","volume":"939520","author":"Ragheb S","year":"2011","journal-title":"Autoimmune Diseases"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.010"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.10.1358"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.174"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-027755"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2010.01.004"},{"key":"ref031","first-page":"45","volume":"23","author":"Yu JJ","year":"2015","journal-title":"Zhongguo Shi Yan Xue Ye XueZa Zhi"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8"},{"key":"ref033","first-page":"68","author":"Thiruppathi M","year":"1274","journal-title":"Ann N Y Acad Sci"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3900"},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03019.x"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000034"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7532-3"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.7.1062-a"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4367"},{"key":"ref041","doi-asserted-by":"crossref","unstructured":"AndersonD, PhanC, JohnstonWS, et al. Rituximab in refractory myasthenia gravis: A prospective, open-label study with long-term follow-uAnn Clin Transl Neurol2016;3:552\u20135.","DOI":"10.1002\/acn3.314"},{"key":"ref042","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.06.151"},{"key":"ref043","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"ref044","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199610)19:10<1239::AID-MUS1>3.0.CO;2-F"},{"key":"ref046","first-page":"265","volume":"88","author":"Dau PC","year":"1982","journal-title":"Prg Clin Biol Res"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-170211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JND-170211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-170211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:53:22Z","timestamp":1777506802000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JND-170211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8,29]]}},"alternative-id":["10.3233\/JND-170211"],"URL":"https:\/\/doi.org\/10.3233\/jnd-170211","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]}}}